{"id":"NCT04382924","sponsor":"Algernon Pharmaceuticals","briefTitle":"Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease","officialTitle":"A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-08-05","primaryCompletion":"2020-12-24","completion":"2021-01-26","firstPosted":"2020-05-11","resultsPosted":"2021-12-03","lastUpdate":"2021-12-03"},"enrollment":168,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["COVID"],"interventions":[{"type":"DRUG","name":"NP-120 (Ifenprodil)","otherNames":[]}],"arms":[{"label":"Treatment Arm A","type":"EXPERIMENTAL"},{"label":"Control Arm","type":"NO_INTERVENTION"},{"label":"Treatment Arm B","type":"EXPERIMENTAL"}],"summary":"The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19. This Protocol is largely based on the recommendations of the World Health Organization (WHO) R\\&D Blueprint Clinical Trials Expert Group COVID-19 Therapeutic Trial Synopsis, and associated Master Protocol.\n\nThe choice of the primary outcome measure will be determined by a pilot study of the first 150 subjects. Subject clinical status (on a 7-point ordinal scale) at day 15 in treatment versus the control group is the default primary endpoint.","primaryOutcome":{"measure":"Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients:","timeFrame":"Day 15","effectByArm":[{"arm":"Treatment Arm A","deltaMin":10,"sd":null},{"arm":"Treatment Arm B","deltaMin":9,"sd":null},{"arm":"Control Arm","deltaMin":18,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"<0.025"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States","Australia","Philippines","Romania"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":52},"commonTop":["Hepatocellular injury","Oral candidiasis","Hyperglycaemia","Hypoalbuminaemia","Constipation"]}}